Assessment of non-invasive NAFDL indices in patients with PCOS

Kovacevic Valentina Elezovic; Sanja Ognjanovic; Bojana Popovic; Dusan Ilic; Palibrk Milica Opalic; Lena Radic; Katarina Krstic; Macut Jelica Bjekic; Milutinovic Danijela Vojnovic; Olivera Stanojlović; Macut Djuro P.

doi:10.1530/endoabs.99.EP151

EP151

Prev Next

Section Contents Cite

Endocrine Abstracts (2024) 99 EP151 | DOI: 10.1530/endoabs.99.EP151

ECE2024 Eposter Presentations Reproductive and Developmental Endocrinology (78 abstracts)

Assessment of non-invasive NAFDL indices in patients with PCOS

Valentina Elezovic Kovacevic ¹ , Sanja Ognjanovic ¹ , Bojana Popovic ¹ , Dusan Ilic ¹ , Milica Opalic Palibrk ¹ , Lena Radic ¹ , Katarina Krstic ¹ , Jelica Bjekic Macut ² , Danijela Vojnovic Milutinovic ³ , Olivera Stanojlović ⁴ & Djuro P. Macut ¹

Err

Author affiliations

¹Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Centre of Serbia, Department for Enocrine Tumors and Hereditary Cancer Syndromes, Belgrade, Serbia; ²Clinical Hospital Centre Bezanijska Kosa, Belgrade, Serbia; ³IBISS, University of Belgrade, Belgrade, Serbia, Belgrade, Serbia; ⁴Institute of Physiology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia

Introduction: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in reproductive-age women. This highly complex reproductive metabolic disorder is independently associated with high prevalence of non-alcoholic fatty liver disease (NAFLD). While the gold standard of NAFLD diagnosis is liver biopsy or MRI, it is costly and hard to perform in large population. Recently, simple and convenient markers, such as liver fat score (LFS), fatty liver index (FLI), and hepatic steatosis index (HSI) have been demonstrated to exhibit comparable coefficient values to standard diagnosis. The aim of this study was to analyse these non-invasive parameters in women with PCOS.

Subjects and Methods: PCOS was diagnosed using ESHRE/ASRM criteria. PCOS group was divided into four phenotypes: PCOS-A (anovulation (ANOV), hyperandrogenism (HA), polycystic ovary morphology (PCOM)), PCOS-B (ANOV, HA), PCOS-C (HA, PCOM) and PCOS-D (ANOV, PCOM). Fatty liver index (FLI), liver fat score (LFS), and hepatic steatosis index (HSI) were used to assess NAFLD. They were calculated according to the previously defined formulas. Values of LFS >−0.640, FLI>60 and HSI>36 was considered as having NAFDL.

Results: We analysed 165 women with PCOS, mean age at diagnosis 25.2±5.1 years and mean BMI 24.1±6.0 kg/m². Most of the group were patients with phenotype A (48.5%), phenotype D (20%), then phenotype B (18.2%) and phenotype C was present in 13.3%. The mean FLI was 21.1±29.2, mean LFS -0.504±2.05 and mean HSI 36.2±5.7. The prevalence of NAFLD in PCOS women evaluated by FLI, LFS and HSI were 14.01%, 36.6 % and 46.4%, respectively. Among phenotypes there were differences in FLI (P-0.0001) and HSI (P-0.036), but not in LFS (P-0.051). Phenotype PCOS-A and PCOS-D shown significant difference in both FLI (P-0.001) and HSI (0.043) as well as PCOS-C vs PCOS-D (FSI P-0.0001; HSI P-0.009); phenotype PCOS-B vs PCOS-C shown difference only in FLI (P-0.01).

Conclusion: In our group, the prevalence of NAFLD varied widely depending on the specific index even though our population is younger and non-obese. Further studies are needed to validate the capacity of NAFLD indices to predict NAFLD in different phenotypes of PCOS.